- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- LIPOSORBER® LA-15
- Device
- Lead sponsor
- Kaneka Medical America LLC
- Industry
- Eligibility
- Up to 75 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 10
- States / cities
- Loma Linda, California • Wilmington, Delaware • Grand Rapids, Michigan + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 80
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome, Membranous Nephropathy, FSGS, MCD, MCD - Minimal Change Disease, Alport Syndrome
- Interventions
- Communication
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 1 Year to 80 Years
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 16
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas + 11 more
- Conditions
- Kidney Diseases, Glomerulosclerosis, Focal Segmental Nephrosis, Lipoid Urologic Disease, Glomerulonephritis, Nephritis, Nephrosis
- Interventions
- GFB-887
- Drug
- Lead sponsor
- Goldfinch Bio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Northridge, California • Victorville, California + 14 more
- Conditions
- FSGS
- Interventions
- APL2, Placebo
- Drug · Other
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • New York, New York
- Conditions
- Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Interventions
- Transcutaneous auricular vagus nerve stimulation, Sham device
- Device
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- New Hyde Park, New York • Philadelphia, Pennsylvania
- Conditions
- Focal Glomerulosclerosis
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)
- Interventions
- Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF), Tacrolimus Capsules, Methylprednisone, Prednisone
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Palo Alto, California • San Francisco, California + 17 more
- Conditions
- Focal Glomerulosclerosis
- Interventions
- Rosiglitazone (Avandia), Adalimumab (Humira)
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 2 Years to 40 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 2
- States / cities
- New Hyde Park, New York • Chapel Hill, North Carolina
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- No intervention
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Pittsburgh, Pennsylvania
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- LIPOSORBER® LA-15 System
- Device
- Lead sponsor
- Kaneka Medical America LLC
- Industry
- Eligibility
- Up to 21 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 12
- States / cities
- Loma Linda, California • Los Angeles, California • Wilmington, Delaware + 9 more
- Conditions
- Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- Interventions
- frexalimab, brivekimig, rilzabrutinib, placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 13 more
- Conditions
- Healthy Volunteers
- Interventions
- GFB-887, Placebo
- Drug
- Lead sponsor
- Goldfinch Bio, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Glomerulonephritis, Nephrotic Syndrome
- Interventions
- Dexamethasone
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- Adalimumab, Lisinopril, losartan, and atorvastatin, galactose
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 1 Year to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 17
- States / cities
- Miami, Florida • Atlanta, Georgia • Kansas City, Kansas + 13 more
- Conditions
- Primary Focal Segmental Glomerulosclerosis
- Interventions
- Obinutuzumab
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy, Minimal Change Disease, Minimal Change Nephrotic Syndrome, IgM Nephropathy, Nephrotic Syndrome, Glomerular Disease, Nephrotic Syndrome, Minimal Change, Nephrotic Syndrome in Children, Nephrotic Syndrome With Edema (Diagnosis), FSGS
- Interventions
- Interview
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy
- Interventions
- Not listed
- Lead sponsor
- Travere Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 487 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- San Francisco, California • Belmar, New Jersey • Chapel Hill, North Carolina + 1 more
- Conditions
- Focal Segmental Glomerulosclerosis (FSGS)
- Interventions
- IXP
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 3
- States / cities
- Miami, Florida • St. Petersburg, Florida • San Antonio, Texas
- Conditions
- Focal Segmental Glomerulosclerosis (FSGS)
- Interventions
- rituximab
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 5 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Kidney Disease, Chronic
- Interventions
- BI 764198, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 20
- States / cities
- Huntsville, Alabama • San Francisco, California • South Gate, California + 17 more
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- Plasma exchange, Cyclophosphamide
- Procedure · Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Kidney Diseases
- Interventions
- H.P. Acthar Gel
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, End Stage Renal Disease, Kidney Failure, Unexplained Proteinuria
- Interventions
- Not listed
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 2,050 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1996 – 2035
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
- Interventions
- Biospecimen collection, Data collection
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan